(CRH) CRH - Overview
Sector: Basic Materials | Industry: Building Materials | Exchange: NYSE (USA) | Market Cap: 67.067m USD | Total Return: 17.7% in 12m
Avg Turnover: 545M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
CRH PLC is a global provider of building materials solutions, headquartered in Ireland and operating primarily across North America and Europe. The company is structured into three segments: Americas Materials Solutions, Americas Building Solutions, and International Solutions. Its product portfolio includes aggregates, cement, ready-mixed concrete, asphalt, and specialized precast concrete products for utility and transportation infrastructure.
The business model relies on vertical integration, controlling the supply chain from raw material extraction in quarries to the delivery of finished architectural products. As a major player in the construction materials sector, CRH is highly sensitive to public infrastructure spending and cyclical trends in the residential and commercial real estate markets. Investors seeking a deeper understanding of these cyclical valuation drivers may find further insights on ValueRay.
The company also provides essential components for critical utility networks, including water, energy, and telecommunications. This infrastructure-heavy focus often results in high barriers to entry due to the significant capital expenditure required for production facilities and the logistical challenges of transporting heavy building materials.
- Federal infrastructure spending in North America drives long term aggregates and cement demand
- Strategic acquisitions and divestitures optimize portfolio margins and accelerate free cash flow growth
- Rising energy and carbon costs impact production expenses for cement and asphalt operations
- Residential construction activity levels influence demand for building solutions and outdoor living products
| Net Income: 5.05b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.89 > 1.0 |
| NWC/Revenue: 10.79% < 20% (prev 16.39%; Δ -5.61% < -1%) |
| CFO/TA 0.09 > 3% & CFO 5.49b > Net Income 5.05b |
| Net Debt (18.5b) to EBITDA (10.9b): 1.70 < 3 |
| Current Ratio: 1.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (668.5m) vs 12m ago -1.21% < -2% |
| Gross Margin: 35.58% > 18% (prev 0.35%; Δ 3.52k% > 0.5%) |
| Asset Turnover: 101.5% > 50% (prev 64.97%; Δ 36.56% > 0%) |
| Interest Coverage Ratio: 6.74 > 6 (EBITDA TTM 10.9b / Interest Expense TTM 1.10b) |
| A: 0.10 (Total Current Assets 16.2b - Total Current Liabilities 10.2b) / Total Assets 58.2b |
| B: 0.43 (Retained Earnings 24.8b / Total Assets 58.2b) |
| C: 0.13 (EBIT TTM 7.42b / Avg Total Assets 55.0b) |
| D: 0.74 (Book Value of Equity 24.7b / Total Liabilities 33.6b) |
| Altman-Z'' = 3.75 = AA |
| DSRI: 0.57 (Receivables 5.21b/5.49b, Revenue 55.9b/33.7b) |
| GMI: 1.00 (GM 35.58% / 35.42%) |
| AQI: 1.08 (AQ_t 0.30 / AQ_t-1 0.27) |
| SGI: 1.66 (Revenue 55.9b / 33.7b) |
| TATA: -0.01 (NI 5.05b - CFO 5.49b) / TA 58.2b) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of May 29, 2026, the stock is trading at USD 106.76 with a total of 2,777,139 shares traded.
Over the past week, the price has changed by +5.23%,
over one month by -6.37%,
over three months by -10.38% and
over the past year by +17.72%.
CRH has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy CRH.
- StrongBuy: 14
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 142.7 | 33.6% |
P/E Trailing = 18.6215
P/E Forward = 17.301
P/S = 1.7621
P/B = 2.9071
P/EG = 2.0241
Revenue TTM = 55.9b USD
EBIT TTM = 7.42b USD
EBITDA TTM = 10.9b USD
Long Term Debt = 16.1b USD (from longTermDebt, last quarter)
Short Term Debt = 2.73b USD (from shortTermDebt, last quarter)
Debt = 21.7b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.88b
Net Debt = 18.5b USD (calculated: Debt 21.7b - CCE 3.24b)
Enterprise Value = 85.6b USD (67.1b + Debt 21.7b - CCE 3.24b)
Interest Coverage Ratio = 6.74 (Ebit TTM 7.42b / Interest Expense TTM 1.10b)
EV/FCF = 29.73x (Enterprise Value 85.6b / FCF TTM 2.88b)
FCF Yield = 3.36% (FCF TTM 2.88b / Enterprise Value 85.6b)
FCF Margin = 5.15% (FCF TTM 2.88b / Revenue TTM 55.9b)
Net Margin = 9.04% (Net Income TTM 5.05b / Revenue TTM 55.9b)
Gross Margin = 35.58% ((Revenue TTM 55.9b - Cost of Revenue TTM 36.0b) / Revenue TTM)
Gross Margin QoQ = 27.75% (prev 35.12%)
Tobins Q-Ratio = 1.47 (Enterprise Value 85.6b / Total Assets 58.2b)
Interest Expense / Debt = 5.07% (Interest Expense 1.10b / Debt 21.7b)
Taxrate = 21.55% (1.04b / 4.83b)
NOPAT = 5.82b (EBIT 7.42b * (1 - 21.55%))
Current Ratio = 1.59 (Total Current Assets 16.2b / Total Current Liabilities 10.2b)
Debt / Equity = 0.94 (Debt 21.7b / totalStockholderEquity, last quarter 23.1b)
Debt / EBITDA = 1.70 (Net Debt 18.5b / EBITDA 10.9b)
Debt / FCF = 6.43 (Net Debt 18.5b / FCF TTM 2.88b)
Total Stockholder Equity = 21.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.18% (Net Income 5.05b / Total Assets 58.2b)
RoE = 23.51% (Net Income TTM 5.05b / Total Stockholder Equity 21.5b)
RoCE = 19.75% (EBIT 7.42b / Capital Employed (Equity 21.5b + L.T.Debt 16.1b))
RoIC = 11.53% (NOPAT 5.82b / Invested Capital 50.5b)
WACC = 9.25% (E(67.1b)/V(88.8b) * Re(10.96%) + D(21.7b)/V(88.8b) * Rd(5.07%) * (1-Tc(0.22)))
Discount Rate = 10.96% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.56 | Cagr: -2.35%
[DCF] Terminal Value 75.11% ; FCFF base≈2.57b ; Y1≈2.94b ; Y5≈4.33b
[DCF] Fair Price = 56.56 (EV 56.3b - Net Debt 18.5b = Equity 37.8b / Shares 668.2m; r=9.25% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 12.06 | EPS CAGR: 1.70% | SUE: 0.02 | # QB: 0
Revenue Correlation: 44.54 | Revenue CAGR: 10.52% | SUE: 0.44 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.06 | Chg30d=-4.47% | Revisions=-60% | Analysts=7
EPS next Quarter (2026-09-30): EPS=2.43 | Chg30d=-1.83% | Revisions=-20% | Analysts=6
EPS current Year (2026-12-31): EPS=5.95 | Chg30d=+0.37% | Revisions=+0% | GrowthEPS=+6.0% | GrowthRev=+6.2%
EPS next Year (2027-12-31): EPS=6.75 | Chg30d=+1.29% | Revisions=+43% | GrowthEPS=+13.4% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: -60%